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Induction of Protective Immunity to Cryptococcal Infection in Mice
by a Heat-Killed, Chitosan-Deficient Strain of Cryptococcus
neoformans
Rajendra Upadhya,a Woei C. Lam,a Brian Maybruck,a Charles A. Specht,b Stuart M. Levitz,b Jennifer K. Lodgea
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USAa; Department of Medicine, University of Massachusetts
Medical School, Worcester, Massachusetts, USAb
ABSTRACT Cryptococcus neoformans is a major opportunistic fungal pathogen that causes fatal meningoencephalitis in immu-
nocompromised individuals and is responsible for a large proportion of AIDS-related deaths. The fungal cell wall is an essential
organelle which undergoes constant modification during various stages of growth and is critical for fungal pathogenesis. One
critical component of the fungal cell wall is chitin, which in C. neoformans is predominantly deacetylated to chitosan. We previ-
ously reported that three chitin deacetylase (CDA) genes have to be deleted to generate a chitosan-deficient C. neoformans strain.
This cda123 strain was avirulent in mice, as it was rapidly cleared from the lungs of infected mice. Here, we report that
clearance of the cda123 strain was associated with sharply spiked concentrations of proinflammatory molecules that are
known to be critical mediators of the orchestration of a protective Th1-type adaptive immune response. This was followed by the
selective enrichment of the Th1-type T cell population in the cda123 strain-infected mouse lung. Importantly, this response
resulted in the development of robust protective immunity to a subsequent lethal challenge with a virulent wild-type C. neofor-
mans strain. Moreover, protective immunity was also induced in mice vaccinated with heat-killed cda123 cells and was ef-
fective in multiple mouse strains. The results presented here provide a strong framework to develop the cda123 strain as a
potential vaccine candidate for C. neoformans infection.
IMPORTANCE The most commonly used anticryptococcal therapies include amphotericin B, 5-fluorocytosine, and fluconazole
alone or in combination. Major drawbacks of these treatment options are their limited efficacy, poor availability in limited re-
source areas, and potential toxicity. The development of antifungal vaccines and immune-based therapeutic interventions is
promising and an attractive alternative to chemotherapeutics. Currently, there are no fungal vaccines in clinical use. This is the
first report of a C. neoformans deletion strain with an avirulent phenotype in mice exhibiting protective immunity when used as
a vaccine after heat inactivation, although other strains that overexpress fungal or murine proteins have recently been shown to
induce a protective response. The data presented here demonstrate the potential for developing the avirulent cda123 strain
into a vaccine-based therapy to treat C. neoformans infection.
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Cryptococcal meningitis is the most frequent result of Crypto-coccus neoformans infection of the central nervous system, ob-
served mainly in patients with AIDS. Worldwide, it has been esti-
mated that cryptococcal meningitis accounts for more than 1
million caseswith about 625,000 deaths annually (1). Even though
infections due to C. neoformans are more common, Cryptococ-
cus gattii is emerging as an important fungal pathogen with signif-
icant virulence, wide-spread environmental prevalence, and the
ability to cause infections even in immunocompetent individuals
(2, 3). The anticryptococcal treatment regimen of choice consists
of a combination of amphotericin B and 5-fluorocytosine. Unfor-
tunately, this combination can have substantial toxicity and is not
available in much of the developing world, where most cases are
seen (4, 5). In some regions, fluconazole is widely used as an alter-
nate to amphotericin B. However, it is not as effective, and there
are reports of strains of C. neoformans that have developed resis-
tance to these drugs (6). Although echinocandins are effective for
treating other fungal infections, they are ineffective against
C. neoformans infections. Therefore, there is an urgent need for
the development of safe and effective treatment strategies
against cryptococcal infections. The development of vaccine-
based immunotherapeutics is an attractive alternative for con-
trolling cryptococcal infections.
Upon entering the host, Cryptococcus is initially challenged by
the complement system and the phagocytic activity of different
innate immune cells. Innate defense is specifically triggered by the
recognition of the pathogen by pattern recognition receptors
(PRRs) on the surface of immune cells. C. neoformans is able to
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modulate host immune responses through a combination of its
polysaccharide capsule- and cell wall-associated mannans, man-
noproteins, glucans, and chitin. The adaptive immune response
against Cryptococcus includes both antibody- and cell-mediated
responses. Effective cross talk between the innate and adaptive
arms of the immune system is critical for the defense against the
pathogen and the resolution of the fungal infection (7–9). It is well
established that cell-mediated immunity (CMI) plays a critical
role in anticryptococcal defense, as is evident from the higher
prevalence of cryptococcal infections in immunocompromised
patients (1). This is recapitulated in animal models of cryptococ-
cosis, where either immunodeficient transgenic mice or mice that
are depleted of CD4 and/or CD8T cells succumb to cryptococ-
cal infectionmore rapidly than immunocompetent mice (10, 11).
To further support the importance of an adaptive response, sev-
eral studies have demonstrated a role for humoral immunity in
contributing to host protection against experimental cryptococcal
infections (12). Antigens demonstrated to induce partial protec-
tive immunity include glucuronoxylomannan (GXM), which is a
component of the cryptococcal capsule, peptide mimotopes of
GXM, complex mixtures of cell surface mannoproteins, and mel-
anin (13–16). Moreover, fungal -glucan particles have been ex-
ploited as an adjuvant and, also, as a vaccine delivery systemdue to
their ability to stimulate dendritic cells to secrete cytokines that
mediate beneficial host immune responses and to cause robust
stimulation of T cells in murine vaccine models (17, 18).
Evidence that a strain of C. neoformans could confer complete
protective immunity came from studies of a C. neoformans H99
strain that was engineered to express and secrete murine gamma
interferon (IFN-). In this case, a protective response was medi-
ated primarily by a Th1-type T cell immune response, without the
contribution of a B-cell mediated processes (19–21). Vaccination
of mice with IFN--expressing C. neoformans (strain H99) re-
sulted in significant increases in the levels of Th1-type proinflam-
matory cytokines and chemokines in the lung, with concomitant
decreases in the levels of cytokines that are mediators of Th2-type
anti-inflammatory activities. This polarized Th1 immunogenic
response was associated with clearance of the H99 cells used for
vaccination and, in turn, induced protective immunity against a
lethal pulmonary infection with wild-type C. neoformans (19).
While the H99 strain described in the above-mentioned study
exploited an inflammatory cytokine of the host to induce protec-
tive immunity, a strain of C. neoformans in which the SLG1 gene
was deleted was recently reported to induce protective immunity
in mice both under immunocompetent and experimentally in-
duced immunocompromised conditions (22). SGL1 encodes a
sterylglucosidase that when deleted results in the accumulation of
sterylglucosides, which in turn modulates immune responses
(23). Therefore, protective immunity developed during infection
with an sgl1 strain is shown to be triggered by theC. neoformans-
derived sterylglucosides (22).
The cryptococcal cell wall is essential for survival, and its com-
ponents are critical formediating host-pathogen interactions. The
modified fungal cell wall architecture in a mutant strain may pro-
voke a different host immune response than its wild-type coun-
terpart during infection. This was recently demonstrated by a
C. neoformans strain engineered to overexpress Znf2, a master
regulator of hyphal development. TheA/Jmouse strain vaccinated
with the Znf2-overexpressing strain showed an altered host im-
mune response that resulted in the induction of protective immu-
nity, even when the strain was heat killed (HK) (24).
The C. neoformans cell wall differs from those of other patho-
genic fungi by the presence of a polysaccharide capsule. In addi-
tion, we have previously discovered that, unlike other yeasts, the
chitin fiber in the cell wall of C. neoformans predominantly exists
in its deacetylated chitosan form under laboratory growth condi-
tions and in the infectedmouse lung (25).We found that deletion
of threeC. neoformans chitin deacetylase genes,CDA1,CDA2, and
CDA3, was sufficient to render the yeast cells devoid of chitosan.
The cda123 strain was avirulent in an inhalation infection
model in mice and was rapidly cleared from the lungs of infected
mice (25). The inability of the mutant yeast cells to deacetylate
chitin results in compromised cell wall integrity, as revealed by
their increased sensitivity to cell wall stressors and alteredmelanin
phenotype (26). Therefore, we hypothesized that chitosan-
deficient yeast cells trigger an altered host immune response com-
pared to the host response to the wild type, which in turn is re-
sponsible for their efficient eradication from the host lung. In the
present study, we extend our observation of rapid mutant fungal
clearance and show that the clearance of the chitosan-deficient
cda123 strain was associated with a strong induction of the
proinflammatory immune response which was able to specifically
attract Th1-type adaptive T cells to the site of infection.We further
demonstrate that pulmonary vaccination with the chitosan-
deficient strainwas able to stimulate a robust protective immunity
to a subsequent lethal challenge with a virulent wild-type C. neo-
formans strain in multiple mouse strains. We also report here that
heat-killed cells of the cda123 strain were able to induce ef-
fective protective immunity to a pulmonary challenge with wild-
type C. neoformans. The observation that viability of the mutant
strain is not required to elicit protective immunity indicates a
means to an even-safer vaccine.
RESULTS
Chitosan-deficient cda123 C. neoformans strain was rap-
idly cleared from the infected mouse lung. We previously re-
ported that the chitosan-deficient cda123 strainwas avirulent
in CBA/J mice when an inhalation mode of infection was used.
This avirulent phenotype was associated with the rapid clearance
of the mutant strain from the infected lung when 105 yeast cells
were used for infection (25). To characterize the host factors po-
tentially responsible for rapidly clearing the cda123 mutant,
we first determined whether the ability of the host to eradicate
fungal cells depends on the number of yeast cells used for inocu-
lation. Therefore, we infected CBA/J mice with 105, 106, and
107 CFU of the wild-type, KN99, and cda123 mutant
strains. At 1, 3, and 7 days postinfection (p.i.), lungs were excised
from the infected mice and the fungal burdens were determined.
Mice infected with 105 CFU of the cda123 strain completely
eliminated live fungal cells by day 3 p.i. (Fig. 1). Mice inoculated
with 106 CFU of the cda123 mutant had cleared more than
99% of the initial inoculum by day 1 p.i., with complete removal
by day 7 p.i. (Fig. 1). Mice infected with 107 CFU of the
cda123 mutant, however, took significantly longer to clear
the yeast cells. At day 1 p.i., 2  106 CFU were recovered, and at
day 7 p.i., there were still ~5,000 CFU recovered in the lungs
(Fig. 1). In a separate experiment, we performed fungal burden
analysis beyond 7 days p.i. for the 107 CFU-infected group and
found no detectable CFU on day 10 p.i., indicating that all live
Upadhya et al.
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chitosan-deficient cells were completely eliminated from the host
lung (data not shown). The fungal burden in the lungs of themice
infected with the wild-type KN99 strain continued to proliferate
as expected (Fig. 1).
Clearance of the cda12 3mutant is associated with ro-
bust stimulation of cytokines that are critical for inducing pro-
tective immunity. To gain insight into the potential role of the
host immune response in clearing the mutant fungal cells, we
analyzed the concentrations of cytokines in lung homogenates at
1, 3, and 7 days p.i. by employing the Bio-Plex promouse cytokine
assay (Bio-Rad Laboratories). We inoculated CBA/J mice with
105, 106, and 107 CFU, as for the clearance studies. Overall, we
found two major factors affecting the type and magnitude of the
host cytokine response (Fig. 2; see also Table S1 in the supplemen-
tal material). First, the number of cells being introduced into the
lung had a major influence on the magnitude of the host cytokine
immune response: 105 CFU gave minimal induction, while
107 CFU elicited maximum induction. This trend was found for
both the wild type and the cda123 strain (Fig. 2A). Second,
the absence of chitosan in the cell wall of the cda123mutant
affected the timing and magnitude of the induction of various
cytokines in the infected lungs. One of the characteristic features
of the immune response triggered by cda123 mutant infec-
tion was that the levels of various cytokines peaked on day 3 p.i.,
before declining sharply on day 7 p.i. to around day 1 p.i. levels
(Fig. 2A). However, in mice infected with wild-type KN99, the
concentrations of many cytokines gradually increased as the in-
fection progressed (Fig. 2A).
We did not find statistically significant differences between the
levels of cytokines in the lungs of mice infected with 105 CFU of
strain KN99 and the cda123mutant (Fig. 2A and B; see also
Table S1 in the supplemental material). However, with higher
inocula, significant differences in the concentrations of cytokines
were observed betweenKN99- and cda123mutant-infected
lungs.With an inoculumof 106 CFU, 14 cytokines (interleukin 1
[IL-1], IL-1, IL-12p70, tumor necrosis factor alpha [TNF-],
CCL3, CCL4, CCL2, IFN-, IL-2, IL-3, IL-4, IL-5, IL-10, and
CCL5) showed significantly different levels in lung lysates of mice
infected with KN99 and cda123 mutant cells on day 3 p.i.
(see Table S1 in the supplementalmaterial).When an inoculumof
107 CFU was used, the levels of 11 of the 23 cytokines tested were
significantly different in the lungs of mice infected with the wild
type and the corresponding cda123 mutant on day 3 p.i.
(Fig. 2A). Importantly, the magnitude of cytokine induction trig-
gered by 107 CFU of the cda123 mutant was distinct and
dramatically higher than for all other infections (Fig. 2B).
We determined the fold induction of cytokines at day 3 p.i. in
variousC. neoformans-infected groups compared to the induction
in the PBS-inoculated control group (Fig. 2B). Then, we com-
pared the cytokine levels induced by 107 CFU of the cda123
mutant to the levels induced by 107 CFU of the wild type and 106
CFU of the cda123mutant.We consistently observed a larger
induction of Th1-associated cytokines in mice infected with 107
CFUof the cda123mutant than inmice infectedwith thewild
type or the lower inoculum of the cda123 strain. TNF-, an
important early-response cytokine, increased about 250-fold in
the lungs of mice infected with 107 CFU of the cda123 mu-
tant, in contrast to 2- to 4-fold increases seen inmice infectedwith
either 107 CFU of KN99 or 106 CFU of cda123 cells
(Fig. 2B). Similarly, in mice infected with 107 CFU of the
cda123 mutant, cytokines IL-12, granulocyte colony-
stimulating factor (G-CSF), IL-1, and IL-1 increased about 45-,
215-, 140-, and 90-fold, respectively (Fig. 2B). IL-12p70 is an im-
portant proinflammatory cytokine that is known to promote the
maturation of naive T cells to helper Th1 cells through the induc-
tion of IFN- (27).While both theKN99 and cda123 strains
induced the upregulation of IL-12p70 in an inoculum size-
dependent manner, its regulation was tightly controlled during
infection with the cda123 mutant compared to its persis-
tently higher levels in the KN99-infectedmurine lung in the later
days of infection (Fig. 2A). G-CSF specifically boosts the prolifer-
ation and maturation of neutrophils (28). The contribution of
IL-1 in resisting fungal infections has been demonstrated using
neutralizing antibodies to IL-1 and using IL-1 receptor-deficient
(IL-1R/) mice (29).
Among the chemokines analyzed, macrophage inflammatory
proteins CCL3 and CCL4, both of which are C-C chemokines,
rose by 435- and 185-fold, respectively, in the lungs of mice in-
fected with 107 CFU of the cda123 mutant, while such a ro-
bust induction was not observed in the lungs of other mouse
groups (infected with the wild type or a lower inoculum of the
cda123mutant) (Fig. 2B).We also saw statistically significant
upregulation in the level of CXCL3, a CXCL-1–type chemokine
that is important for attracting neutrophils to the site of infection,
in the lungs of mice infected with 107 CFU of the cda123
mutant (Fig. 2B). All the above-mentioned cytokines have been
demonstrated to create an environment conducive for the devel-
opment of a protective Th1-type adaptive immune response (30).
In contrast, even though we observed statistically significant dif-
ferences in the induction levels of IL-4 and IL-10 in mice infected
with 107 CFU of the cda123 mutant and mice infected with
107 CFU of the wild type, the magnitudes of upregulation for
infection with 107 CFU of the cda123mutant were small (5-
to 10-fold) compared to the levels seen for the Th1-specific in-
FIG 1 The time required for the host to completely eradicate chitosan-
deficient cda123 cells in the lung depends on the size of the yeast inocu-
lum. CBA/Jmice were inoculated with various doses (equivalent to 105, 106, or
107 CFU) of either strain KN99 or cda123 mutant cells through intra-
nasal inoculation. At 1, 3, and 7 days p.i., lungs were harvested, homogenized,
and serially diluted for CFU enumeration by plating on YPD. Fungal burden is
expressed asCFUper lung. The detection limit of the assaywas10CFU/lung.
Error bars indicate standard errors of the means for three mice per treatment
group.
Chitosan-Deﬁcient Fungus Induces Protective Immunity
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flammatorymoleculesmentioned above (Fig. 2B andC). IL-4 and
IL-10 are cytokines with known roles in the Th2-type immune
response that are also known to facilitate fungal pathogenesis
(31, 32).
Overall, we found that infection by and subsequent clearance
of the cda123 strain triggered a host immune response char-
acterized by significant, although temporally limited stimulation
of cytokines known to be important for orchestrating a protective
FIG 2 The kinetic profiles of mouse pulmonary cytokines were dependent on the inoculum load of C. neoformans cells and the presence or absence of chitosan
in the cell wall. (A) Representative cytokine profiles in the lungs at various times after infecting the mice with various doses (equivalent to 105, 106, or 107 CFU)
of either KN99 or cda123 cells. Pulmonary cytokines that showed significantly different levels at day 3 p.i. in mice infected with 107 CFU of KN99 or the
cda123mutant, in two independent experiments with three mice per treatment group, are displayed. Error bars indicate standard errors of the means. (B)
Data from panel A are expressed as fold induction in protein levels of cytokines on day 3 p.i. in the lungs of the mice infected with various doses of either the
cda123 mutant or KN99 compared to their levels in the PBS-inoculated control mouse lungs (n  3). ****, P  0.0001 by two-way ANOVA and
Bonferroni’s multiple comparisons test. For IL2p70, **, P 0.0053, and *, P 0.0193; for CCL2, **, P 0.002; for CXCL3, ***, P 0.0006, and *, P 0.026;
for IL-4, **, P 0.0027, and *, P 0.05; and for IL-10, ***, P 0.0009. All data are presented as mean values standard errors of the means (SEM). (C, D)
Selective high-level induction of Th1-associated cytokines was observed only in cda123-infectedmouse lungs (C), while their upregulationwas not as robust
in KN99-infected mouse lungs (D). The intensity of upregulation of Th2-associated cytokines was not as dramatic as that of the Th1 cytokines. The cytokine
levels for each group were normalized to the results for the PBS control group.
Upadhya et al.
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Th1-type environment in the lung (Fig. 2C). This Th1 cytokine
enrichment in the lungs of mice infected with 107 CFU of the
cda123mutantwas in conjunctionwith lower levels of induc-
tion of the Th2-type cytokines IL-4, IL-5, IL-10, and IL-13. This
suggested to us that the chitosan-deficient cda123 C. neofor-
mans cellsmay be capable of skewing the host immune response in
favor of a Th1-type adaptive response.
Pulmonary inflammatory response triggered by infection
with 107 CFU of the cda123mutant was followed by a spe-
cific increase in the recruitment of Th1 CD4 T cells in the in-
fectedmouse lung.Weconducted apulmonary leukocyte analysis
to study the recruitment of adaptive immune cells in response to
infection. We infected mice with 107 CFU of either KN99 or the
cda123mutant, and at days 1, 3, 7, 10, and 21 p.i., excised the
lungs and prepared single-cell suspensions for analysis by multi-
color flow cytometry. Since mice infected with KN99 did not
survive beyond 19 days, theywere not available for leukocyte anal-
ysis on day 21 p.i. The total number of leukocytes (i.e., CD45) in
the lungs was significantly higher for mice infected with the
cda123 mutant than for either KN99-infected or PBS con-
trol mice on day 3 p.i. (P 0.05), which reached similar levels at
the later stages of infection (Fig. 3A). However, the number of
leukocytes in the KN99-infected mice was not significantly
higher than for the PBS control group on day 3. Similarly, there
were significant increases in the numbers of neutrophils on days 1
(P 0.0034) and 3 (P 0.01) p.i. in the lungs of themice infected
with cda123 mutant compared to the numbers in KN99-
infected mice (Fig. 3B). However, no statistical differences were
found between the total numbers of macrophages, dendritic cells,
eosinophils, total CD4 and CD8 T cells, Th17 cells, and Treg
cells for KN99 and cda123 mutant infection at each time
point (data not shown). The frequencies of CD4 T cells with a
Th1 phenotype (CD45 CD3 CD4 CD183 CD196) were
significantly higher in the lungs of mice infected with cda123
cells (P  0.05) than in KN99-infected lungs on day 10 p.i.
(Fig. 3C). In contrast, the number of CD4 Th2 cells (CD45
Chitosan-Deﬁcient Fungus Induces Protective Immunity
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CD3 CD4 CD183 CD196) was significantly lower in
cda123 mutant-infected lungs than in wild type-infected
lungs (P 0.05) on day 10 p.i. (Fig. 3D). Furthermore, significant
populations of Th1 cells were found to express CD44 onday 10 p.i.
only in the lungs of cda123mutant-infected mice and not in
the lungs of eitherKN99-infectedmice (P 0.05) or PBS control
mice (P 0.0005) (Fig. 3E). High expression of CD44 receptor is
associated with the expansion of Th1 cells into antigen-
experiencedmemory cells (33). Taken together, the abundance of
Th1-type T cells that were also CD44-expressing memory cells in
the cda123 mutant-infected mouse lungs indicated that a
host immune response triggered during the clearance of
cda123 cells might induce protective immunity to subse-
quent C. neoformans infection.
Immunizingmicewith cda123 cells conferred complete
protection to subsequent challenge with highly virulent wild-
type C. neoformans cells. To evaluate whether the pulmonary
immune response elicited by the cda123mutant and the sub-
sequent increased recruitment of Th1-type CD4 T cells is able to
trigger protective immunity, we first infected CBA/Jmice with 107
CFU of cda123 cells in PBS through intranasal inoculation.
Mice inoculated with PBS served as a control group. Mice were
allowed 40 days to resolve the infection and then were challenged
intranasally with 105 CFU of the wild-type KN99 strain. Mice
preinfected (immunized) with the cda123 strain were com-
pletely protected, while the PBS control group mice exhibited
100% mortality by day 19 postchallenge (Fig. 4). On day 80 p.i.,
the study was ended and the lung and brain homogenates of mice
were plated for enumerating fungal CFU. We found that the fun-
gal burden was restricted to the lung and was approximately equal
to the challenge inoculum of 105 CFU (data not shown).
Heat-killed cda123 cells are equally effective in induc-
ing strong protective immunity to C. neoformans infection. To
determine whether any biological activity present in the
cda123 strain is specifically required for inducing protective
immunity in mice, we wanted to test the feasibility of using its
heat-killed (HK) cells as a vaccine.Wedetermined that incubation
of either KN99 or cda123 cells at 70°C for 15min resulted in
the complete loss of their viability, and we proceeded to inoculate
mice intranasally with 107 CFU of HK cells. At 40 days p.i., mice
were challenged with 105 CFU of the wild-type strain KN99. We
observed that mice inoculated with either PBS or HKKN99 suc-
cumbed to the KN99 challenge infection by day 19 (Fig. 5A).
However, the mice vaccinated with HK cda123 cells were
completely protected throughout the period of the experiment
(80 days) (Fig. 5A). Similar to the results for vaccination with live
FIG 3 Pulmonary leukocyte analysis revealed increased recruitment of Th1-
type CD4 T cells in the lungs of mice infected with the chitosan-deficient
cda123 C. neoformans cells. (A, B) Mice inoculated with 107 CFU of the
cda123 strain exhibited significant enrichment of total leukocytes (A) and
neutrophils (B) in the lungs on day 3 p.i. compared to their levels in the lungs
of mice inoculated with either 107 CFU of KN99 or 50 l of PBS. (C) The
populations of CD4 Th1 cells on days 10 and 21 p.i. were significantly higher
in the cda123 mutant-infected mouse lungs than in the lungs of either
PBS- or KN99-inoculated animals. (D) The frequencies of Th2-type CD4
leukocytes on day 10 p.i. were significantly higher in the KN99-infected an-
imals than in either PBS- or cda123-inoculated animals. (E) Th1 cells
induced during infection with cda123 cells showed increased expression
of CD44 on their surface on day 10 p.i., and this was maintained during im-
mune homeostasis (day 21 p.i.). The gating strategy for total leukocytes, neu-
trophils, Th1 and Th2 cells, and CD44 expression on Th1 cells per whole lung
was based upon these leukocyte populations being CD45, CD45 CD24
CD11c Siglec F-LY6G, CD45 CD3 CD4 CD183 CD196, CD45
CD3 CD4 CD183 CD196, and CD45 CD3 CD4 CD183 CD196
CD44, respectively. The total number of leukocytes was calculated by multi-
plying the frequency of the leukocyte by the total number of cells determined
from the single-cell mouse lung suspensions. Data are presented as the mean
results  standard deviations for three mice per group from one biological
experiment. Means were compared among groups within each day using one-
way ANOVA followed by the Bonferroni multiple-comparison test. *, P 
0.05; **, P 0.01.
FIG 4 Vaccination of CBA/J mice with 107 CFU of live cda123 cells
conferred robust protective immunity to subsequent infection with wild-type
KN99C. neoformans cells.Micewere inoculatedwith 107CFUof cda123
cells through inhalation. PBS-inoculatedmice served as control. Animals were
left for 40 days to resolve the infection. Subsequently, both groups ofmicewere
challenged with 105 CFU of KN99 cells. Virulence was recorded as mortality
of mice. Mice that lost 25% of starting body weight were considered to be
moribund and were sacrificed. The percentage of mice that survived was plot-
ted against the day p.i. Each survival curve is the average of three independent
experiments that had five mice per experimental group.
Upadhya et al.
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cda123 cells, the fungal burden in the surviving mice was
restricted to the lungs, with no dissemination to brain, spleen, or
kidneys (data not shown). When 50,000 CFU of KN99 was used
for challenging mice, we found on average an 85% decrease in the
lung CFU on day 70 after the challenge infection, suggesting that
HK cda123mutant-induced protective immunity has the ca-
pacity to contain and partly clear an otherwise lethal infection.We
also observed in a separate experiment that mice vaccinated with
HK cda123 cells and later challenged with 50,000 CFU of
KN99 cells survived for 140 days postchallenge, atwhich time the
experiment was terminated (data not shown). Surviving mice
from both these experiments showed various levels of fungal
clearance, with some mice showing no fungal burden in the lung
(Fig. 5B). In allmice, the fungal burdenwas restricted to the lungs.
In the experiment that was ended on day 70, mice had a median
fungal burden in the lungs of about 8,000CFU/lung (Fig. 5B). The
median fungal burden for the experiment that was ended on day
140 was around 5,500 CFU/lung (Fig. 5B).
Based upon our discovery that animals infected with 107 CFU
of cda123 cells responded with a vigorous induction of pro-
inflammatory cytokines in the lungs, while the cytokine response
was less dramatic in the mice infected with either 105 or 106 CFU,
we wondered whether vaccination with lower doses (105 or
106 CFU) of heat-killed cda123 cells could induce protective
immunity. To test this, we vaccinated mice with doses of 105, 106,
and 107 CFU of HK cells of either wild-type KN99 or the
cda123mutant. We found that mice vaccinated with 107 HK
cda123 cells were the only group that was able to mount a
robust protective response to a subsequent lethal challenge with
KN99 (Fig. 5C). Mice vaccinated with lower numbers of
cda123 cells succumbed to infection similarly to those in the
unvaccinated group, with a median survival time of between 20
and 22 days postchallenge (Fig. 5C). These data further support
the requirement of a minimum dose of antigen to induce an ef-
fective early innate response for successful priming of an adaptive
immune response.
Vaccination of mice with the C. neoformans cda123
strain confers significant cross protection against subsequent
pulmonary challenge with a lethal dose ofC. gattii. Even though
C. neoformans and C. gattii are closely related species, they differ
significantly in their natural habitats, in the clinicalmanifestations
of the disease they cause, in the specificity toward the organs they
target in themurine infectionmodel, in their carbon and nitrogen
assimilation pathways, and finally, in the types of host immune
response they provoke (34, 35). The differences in the immune
responses they induce suggest that there may be differences in the
organization of antigens on the cell surface of these two species.
Therefore, we tested whether vaccination of mice with the
cda123 mutant generated in a C. neoformans background
would protect them from a subsequent challenge with C. gattii.
Using the vaccination and infection protocol described above, we
challenged mice vaccinated with HK cells of the C. neoformans
cda123mutant with 105 CFU of eitherC. gattii strain R265 or
C. gattii strain WM276. Mice vaccinated with PBS served as a
sham vaccination control. We observed that control mice chal-
lenged with either C. gattii R265 or C. gattii WM276 had mean
survival times of 18 and 17 days, respectively (Fig. 6). On the other
hand, mice that were vaccinated with the C. neoformans
cda123 strain exhibited significantly delayed mortality, with
FIG 5 Heat-killed (HK) cda123 cells of C. neoformans induced strong
protective immunity to a subsequent challenge with wild-type KN99 infec-
tion. (A) Mice were immunized with 107 CFU of HK cells of either the wild-
type KN99 or the cda123 strain. Controlmice were inoculatedwith PBS.
After 40 days, mice were challenged with 105 CFU of wild-type KN99 cells.
Survival of the animals was recorded as described above. The data shown are
the average results from four experiments with five mice per experimental
group. (B) Pulmonary fungal burden analysis of themice that were vaccinated
initially with 107 HK cda123 cells and later challenged with 50,000 viru-
lent KN99 cells. At 70 days p.i., lungs were harvested and fungal CFU were
enumerated. (C) Mice were vaccinated with various doses (105, 106, or
107 CFU) of HK cells of either the wild-type KN99 or the cda123 strain.
After 40 days, they were challenged with 50,000 wild-type KN99 cells. Sur-
vival of the mice was monitored as described above.
FIG 6 Vaccination of mice with HK cells of cda123 C. neoformans con-
ferred partial protection to subsequent challenge with a lethal dose of a wild-
type strain of C. gattii. A group of 10 mice (CBA/J) was subjected to initial
vaccinationwith 107HK cda123 cells and later challengedwith 105CFUof
eitherC. gattiiR265 orC. gattiiWM276. Survival of themice wasmonitored as
described above. PBS-inoculated mice served as control.
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mean survival times of 33 and 30 days forC. gattiiR265 andC. gat-
tiiWM276, respectively. This demonstrated that some cross pro-
tection developed with the C. neoformans cda123 vaccine.
Heat-killed cda123 cell-induced protective immunity
to C. neoformans infection is effective in multiple strains of
mice. Previous work by several laboratories demonstrated that
mice of different genetic backgrounds exhibit various levels of
sensitivity to cryptococcal infection (36–38). Therefore, we chose
to test the effectiveness of the cda123 mutant vaccination in
C57BL/6, 129, A/J, and BALB/c inbred mice. We vaccinated
C57BL/6 mice with 107 CFU of live cda123 cells and, after
40 days, challenged themwith 105 CFU of KN99. Vaccination of
C57BL/6 mice with the cda123 strain conferred a partial but
significant level of protection, with amean survival time of 48 days
compared to 16.5 days in the unvaccinated control group
(Fig. 7A).
We then vaccinated 129, A/J, and BALB/c mice with 107 HK
cda123 cells. The A/J and 129 mice were protected similarly
to theCBA/Jmice (Fig. 7B andC). All vaccinated animals survived
the challenge with the KN99 strain for the length of the experi-
ment (80 days postchallenge). However, for BALB/c mice, the
efficacy of the cda123mutant vaccine was slightly decreased
(Fig. 7D). Of the fivemice used for the experiment, three survived
the infection, while two succumbed, on day 46 and day 64
(Fig. 7D). All mice either inoculated with PBS or vaccinated with
an HK preparation of KN99 cells succumbed by 23 days post-
challenge. Among these control groups, the A/J mice were the
most sensitive to KN99 challenge, with amedian survival time of
15 days, while 129 and BALB/c mice showed median survival
times of 22 and 23 days, respectively. We also observed significant
but varied clearance of infection in vaccinated mice of different
genetic backgrounds (Fig. 7E).
DISCUSSION
Our initial goal for the investigation was to understand the mech-
anism of the clearance of chitosan-deficient mutant strains of
C. neoformans in the mouse lung. In our previous study, we re-
ported that cells of C. neoformans chs3, csr2, and cda123
mutant strains were devoid of chitosan and displayed compro-
mised cell wall integrity (26). Interestingly, while the chs3 and
csr2 strains were temperature sensitive, the cda123 strain
was able to grow at host body temperature. Therefore, we selected
the cda123 strain to further understand the mechanism of its
clearance from the mouse lung. Since 105 CFU of the cda123
FIG 7 Protective immunity induced by HK cda123 cells was effective in different inbred mouse strains. (A) A group of 10 C57BL/6 mice were vaccinated
with 107 CFU of live cda123 cells and later challenged with 105 CFU of KN99 cells as described above. Survival was monitored, and the percentage of
survival was plotted against the day postchallenge. (B to D) Groups of five mice each of strains 129 (B), A/J (C), and BALB/c (D) were vaccinated with 107 HK
cda123 cells. At 40 days postvaccination,micewere challengedwith 50,000wild-typeKN99 cells. Survival wasmonitored as described above. (E) At 80 days
postchallenge, lungs from the surviving mice from the experiment whose results are shown in panels B, C, and D were harvested and subjected to lung fungal
burden analysis.
Upadhya et al.
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mutant were cleared in 24 h, we wondered whether increasing the
CFU of the inoculum would alter clearance (25). We found that
using higher inocula delayed complete eradication (Fig. 1). More-
over, when 107 CFU of the cda123mutant were used, we did
recover 5,000 CFU of cells from the infected lung at 7 days p.i.,
showing that cda123 cells were able to survive in the host. It
will be interesting to see whether those that survived for 7 days
were the product of newly replicated fungal cells or persisted from
the original inoculumwithout replication. Nevertheless, the com-
plete clearance of cda123 cells from themouse lung by day 10
p.i. suggested that host-specific mechanisms may be responsible
for clearing the chitosan-deficient mutant cells, as opposed to the
mere inability of the cda123 cells to survive or grow in the
host lung.
The results from using increasing sizes of cda123 inocula
for intranasal inoculation not only suggested the potential role of
host factors in eradicating themutant fungal cells but also implied
that the intensity of the host immune response was dependent on
the size of the initial infection. We chose to measure cytokine
levels in lung homogenates as a measure of the host response.
Infection with 105 CFU resulted in the detection of low levels of
cytokines on different days p.i. This may be due to either the
limitations in the sensitivity of the assay employed or the difficulty
in choosing an ideal time point for cytokine analysis due to the
dynamic nature of the inflammatory response induced. More-
over, at this size of inoculum, we did not find a statistically signif-
icant difference between the levels of cytokines in KN99- and
cda123mutant-infected murine lungs. However, there were
statistically significant differences between the amounts of various
cytokines in the lung homogenates of mice infected with KN99
and with the cda123 mutant for mice inoculated with both
106 and 107 CFU, and the magnitude of their induction on day 3
p.i. was clearly different for the mice infected with 107 CFU.
TNF- has been shown to be necessary for the development of
Th1-mediated immunity and plays a pivotal role in clearing vari-
ous fungal infections, including C. neoformans infection, in ani-
malmodels (reference 39 and references therein). The production
of TNF- in the afferent phase (0 to 7 days p.i.) of the host im-
mune response has been demonstrated to be critical for the devel-
opment of protective immunity to C. neoformans infection in the
CBA/J mouse model (40). Such a dependency of cda123
mutant-induced protective immunity on the early expression of
TNF-may be playing a role in our experiments. While infection
with 105 and 106 CFU of cda123 cells did not elicit significant
TNF- induction, infection with 107 CFU of the cda123mu-
tant clearly produced a dramatic spike in its levels in the lung on
day 3 p.i. Accordingly, vaccination with 105 and 106 CFU of the
cda123mutant did not confer any protection. However, ro-
bust protection was observed when 107 CFU of the cda123
mutant was used for vaccination. Therefore, vaccination experi-
mentswhen performed in the presence of TNF--specific neutral-
izing antibodies may shed light on the essential nature of early
TNF- induction during vaccination, on the clearance of the
cda123 strain, and on subsequent induction of effective pro-
tective immunity to C. neoformans infection. More importantly,
the increased levels of TNF- detected during infection with 107
cda123 cells did not persist after 3 days p.i. This might per-
haps have prevented deleterious damage to the host lung due to an
unregulated TNF--mediated inflammatory response. Several
fungus-related virulence factors, such as polysaccharide capsule,
melanin, and prostaglandinlike molecules, have been docu-
mented to inhibit the stimulation of TNF- during wild-type
C. neoformans infection (41–43). However, determination of cel-
lular factors associated with the cda123 strain that resulted in
the controlled expression of TNF- production during infection
will provide more insight into the regulation of TNF- during
C. neoformans infection. In any case, this effect of the cda123
strain in controlled regulation of TNF- expression during vacci-
nationmay be an added benefit as far as the safety of the vaccine is
concerned.
IL-12 is a heterodimeric cytokine that has been shown to be
essential for the development of a protective Th1 response and
resistance to C. neoformans infection, and its expression is under
the influence of TNF- (39, 44, 45).We found that the expression
of IL-12p70 in both KN99- and cda123 mutant-infected
lungs followed the pattern of TNF- expression (see Table S1 in
the supplemental material). We did not detect significant differ-
ences between the levels of either IFN- or IL-2 in KN99- and
cda123 mutant-infected mouse lungs at the chosen time
points. Thismay be due to the complex and dynamic nature of the
regulation of cytokine expression, the limited number of time
points chosen in our experiment for cytokine analysis, or the lim-
itations in the sensitivity of the assay employed.
IL-1 and IL-1 both belong to the IL-1 family of proinflam-
matory cytokines that play a major role in the host’s defense
against infections, not only by activating innate immune cells but
also by triggering further release of proinflammatory cytokines
that participate in the modulation of the host adaptive immune
response. The critical role of IL-1 in controlling C. neoformans
and other pathogenic fungal infections through the activation of
the NLRP3 inflammasome has recently been documented (46–
48). We do not know the source of IL-1 in the present study;
however, dendritic cell-derived IL-1 has been shown to be im-
portant for effective priming of T cells (49). Moreover, when re-
combinant IL- was used as an adjuvant together with a heat-
killed formulation of a weak attenuated strain of Blastomyces
dermatitidis, it enhanced the protective effect of the vaccine strain
(50). Even though infecting mice with 107 CFU of KN99 caused
the stimulation of both IL-1 and IL-1, the levels were only
comparable to those induced by infection with 106 CFU of the
cda123 mutant, which was nonprotective. Therefore, the
timing (3 days p.i.) and the effective concentration of both IL-1
and IL-1 induced by 107 CFU of the cda123 mutant may
have contributed to the protective immunity.
CCL3 is a C-C chemokine that acts as a chemoattractant for
leukocytes, is critical for the promotion of the Th1-type immune
response, inhibits the expression of IL-4/IL-13, and plays an im-
portant role in preventing lung eosinophilia duringC. neoformans
infection (51, 52). Of all the cytokines tested, CCL3 showed a
maximum intensity of induction in the cda123 mutant-
infected mouse lung which was specific to mice infected with
107 CFU of cells, similar to the response seen for TNF-. Consis-
tent with this, we saw a significant increase in leukocyte migration
to the lungs on day 3 p.i. in the 107 cda123 mutant-infected
mouse lung compared to that in the KN99-infectedmouse lung.
Therefore, CCL3 may be one of the important cytokines respon-
sible for the migration of leukocytes to the lung. These results,
along with the previously documented requirement of early in-
duction of CCL3 duringC. neoformans infection in promoting the
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Th1-type protective cellular response, suggest a role of CCL3 in
the cda123mutant-induced protective immunity (52).
CCL2 is a potent chemotactic factor for monocytes and den-
dritic cells, in addition to its role in regulating the migration and
infiltration of memory T-lymphocytes and natural killer (NK)
cells. The role of CCL2 in inducing Th1 protective immunity and
fungal clearance during C. neoformans infection has been demon-
strated by its involvement in recruiting macrophages, CD4 T
cells, and NK T cells to the site of infection (53, 54). Even though
we observed increased levels of CCL2 in the lungs of mice infected
with 107 CFU of the cda123 mutant, significantly increased
levels of CCL2 were also seen in mice infected with 107 CFU of
strain KN99. These results suggest a minimal role of CCL2 in
cda123mutant-induced protective immunity.
CXCL3 is a CXCL1 type of chemokine that is associated with
neutrophil recruitment. The contribution of CXCL3 in inducing
resistance to C. neoformans infection is not well characterized.
However, we observed that this chemokine was significantly ele-
vated in murine lungs infected with 107 CFU of the cda123
mutant. This is consistent with previously published results show-
ing the expression pattern of CXCL3 during infection of the SJL/J
mouse strain that is resistant to a moderately virulent strain of
C. neoformans (strain 24067) (55). The higher concentration of
CXCL3, followed by the increased number of neutrophils in the
lungs of mice infected with 107 CFU of the cda123 mutant,
may indicate an important role of this chemokine in the clearance
of the cda123 mutant and in the induction of adaptive im-
munity. In addition, the significant increase in the levels ofG-CSF,
only in the lungs ofmice infected with 107 CFU of the cda123
mutant,might have promoted the proliferation andmaturation of
neutrophils, which is consistent with previously published results
showing a beneficial role of recombinant G-CSF therapy during
bacterial and opportunistic fungal infections (28). Furthermore,
recombinant human G-CSF has been reported to enhance the
ability of human effector cells to kill C. neoformans (56). There-
fore, we speculate that this property of G-CSF may be conserved
andmay be partly responsible for the clearance of the cda123
mutant. Cytokines secreted upon the infiltration of potent neu-
trophilsmight have contributed to the eventual polarization of the
adaptive immunity and the subsequent protection against wild-
type C. neoformans challenge.
The selective induction of the above-mentioned proinflamma-
tory cytokines during infection with 107 CFU of the cda123
mutant was associated with minimal changes in the concentra-
tions of cytokines driving aTh2 response, such as IL-4, IL-5, IL-10,
and IL-13 (Fig. 2C). A Th2-type T cell response exacerbates
C. neoformans infection by allowing fungal proliferation (31, 57).
Overall, our cytokine analysis suggested an overwhelming proin-
flammatory response that should direct Th1 skewing of the early
host immune response. This was supported by the results of mul-
ticolor flow cytometry, which showed an increase of Th1-type
cells in the infected lung on day 10 p.i. This immunological data
prompted us to evaluate whether chitosan-deficient cda123
cells can induce protective immunity.
Unlike C. neoformans, C. gattii causes disseminated infections
in immunocompetent and apparently healthy individuals. C. gat-
tii strain R265, which was responsible for the Pacific Northwest
outbreak, was found to be more virulent than C. gattii strain
WM276, an environmental isolate fromAustralia, when tested for
virulence in either C57BL/6 or A/JCr mice (58). Interestingly, we
observed similar levels of virulence for these strains in the CBA/J
mouse model both in the immunized and naive mouse groups. It
is encouraging that the cda123mutant engineered in C. neo-
formans generated significant cross protection to C. gattii infec-
tions. This is most likely due to the presence of common immu-
nodominant proteins in the cell wall fraction of both
C. neoformans and C. gattii (30, 59). However, the failure of the
C. neoformans cda123 vaccine to confer complete protection
against C. gattii infection emphasizes the underlying differences
between the antigenic determinants in these two species of Cryp-
tococcus. In addition, previous studies have reported that C. gattii
infection causes inhibition of efficient neutrophil migration and
pulmonary cytokine production and downregulation of the den-
dritic cell-mediated Th1 immune response (34, 58). Therefore, it
is plausible that challenging cda123 strain-vaccinated mice
with C. gattiimight have decreased the intensity of the protective
host inflammatory response, which in turn resulted in the less-
effective cross protection observed in our experiments. Themech-
anisms of chitin and chitosan biosynthesis and its regulation in
C. gattii have not been studied. It will be interesting to see whether
vaccination with a cda123 strain engineered in C. gattii con-
fers complete protection against C. gattii infections.
Several studies have demonstrated the influence of host genetic
factors on the susceptibility to Cryptococcus infection (36, 37).
CBA/J mice have been demonstrated to be resistant to C. neofor-
mans strain 52 D by developing a strong Th1 adaptive immunity
that results in the progressive clearance of the infection. In con-
trast, C57BL/6 mice respond with a skewed Th2 response and
succumb to infection. In such infection experiments, BALB/c
mice have exhibited an intermediate phenotype (57). These pat-
terns are mirrored by the results of our vaccination and challenge
experiments. CBA/J mice showed a strong resistance to infection
after vaccination, with significant clearing, while the efficiency of
protection was slightly reduced in BALB/c mice and appreciably
decreased inC57BL/6mice. Interestingly, all the survivingBALB/c
mice showed significant clearance of the challenge inoculum. The
vaccination of 129 and A/J strains with the cda123 mutant
resulted in the generation of protective immunity similar to that in
the CBA/J strain, with all mice showing clearance of the challenge
inoculum to various degrees. Even though naive A/J mice were
more sensitive to C. neoformans infection than 129 and BALB/c
mice, they were able to mount a strong protection after vaccina-
tion.
Previous reports have shown that commercial and fungal chi-
tin preparations elicit potent immune responses in the host (60–
62). The type of immune response stimulated by a chitin prepa-
ration depended on its source, size, purity, and concentration in in
vitro and in vivo studies (63, 64). Purified chitosan also stimulates
immune responses, including inflammasome activation, which
suggests a proinflammatory role for chitosan as well (65). How-
ever, the biological context of thematerial being presentedmay be
crucial for how it is interpreted by the host. Additional pathogen-
associated molecular patterns (PAMPs) present in the wild-type
cell surface may be modulating a host response to whole Crypto-
coccus cells that is distinct from the response to purified chitosan.
We have previously shown that all of the chitin-derived fiber in
the cda123mutant andmost of the chitin-derivedmaterial in
chs3 and csr2 cells exists in its fully acetylated chitin form.
These chitosan-deficient mutants exhibited sensitivity to cell wall
stressors and a leaky melanin phenotype, suggesting a potentially
Upadhya et al.
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disorganized cell wall architecture with possible exposure of un-
derlying chitin and other immunogenic molecules on the cell sur-
face which, in turn, may have resulted in the induction of a strong
host immune response (26). It is possible that the chitin induces
the protective immune response. The nature of the chitin fiber
present in the cda123, chs3, and csr2 strains is not known,
but all of the strains were cleared rapidly from the infectedmurine
lung (25). In the case of the chs3 and csr2 strains, their clearance
can almost surely be attributed in part to their temperature-
sensitive phenotype. However, whether their clearance is followed
by a concomitant polarization of the host immune response to-
ward Th1 adaptive immunity is yet to be determined, which may
provide more insight into the connection between chitin/cell wall
structure and the host immune response. In wild-type cells, the
presence of chitosan may mask the exposure of the chitin, result-
ing in a subdued host inflammatory response. It is possible that
the host response is due to the exposure of chitin and not the
quantity of chitin in the cell wall.
Various C. neoformans cell wall-associated proteins have been
shown to induce a proinflammatory response thatwas followedby
partial protection against C. neoformans infection when they were
used as vaccines by themselves or in conjunctionwith yeast glucan
particles (18, 59). Lack of chitosan in the cda123 strain may
have resulted in the exposure of these antigenic cell wall proteins
and other potential PAMPs which, in addition to the potent im-
munomodulatory property of chitin, may have contributed to the
mechanisms of protective immunity. Comparison of the surface-
exposed PAMPs on additional chitin or chitosan mutants or mu-
tants with othermutations that affect the cell surface, such as Znf2
overexpression (which causes a morphogenesis defect) and
Rim101 deletion (which causes cell wall defects), and the nature of
the host immune responses may lead to a better understanding of
the molecular signals that drive the protective response (24, 66).
In the absence of potent subunit vaccines that confer complete
protection, the use of attenuated strains as potential vaccine can-
didates is one of the most promising approaches. The finding that
HK cells of the cda123 mutant conferred protective immu-
nity makes it attractive for development into a safe vaccine for
clinical use.
MATERIALS AND METHODS
Mice. All mice used were females between 6 and 8 weeks old. CBA/J,
C57BL/6, 129, BALB/c, and A/J mice were from The Jackson Laboratory
(Bar Harbor, ME). Mice were housed at the Washington University
School of Medicine and handled according to guidelines approved by the
Institutional Animal Care and Use Committee.
Cryptococcus strains. C. neoformans strain KN99 and the
cda123 (LBCN 632) strain derived from it were described previously
(25). C. gattii strain R265 is a representative of the common VGIIa mo-
lecular subtype and is from the outbreak in British Columbia. C. gattii
strainWM276 is a representative of subtype VGI and is an environmental
isolate from Australia. Both of these strains were kindly provided by Jo-
seph Heitman (Duke University Medical Center). Cells were recovered
from 80°C stocks prior to use in each experiment. The strains were
cultured in yeast extract-peptone-dextrose (YPD) medium.
Pulmonary infections. Yeast strains were grown in 50 ml of YPD
medium in a 250-ml Erlenmeyer flask (Corning Incorporated, Tewkes-
bury, MA) for 36 h at 30°C and at 300 rpm in a shaking incubator. Cells
were harvested by centrifugation at 1,800  g for 10 min, washed twice
with phosphate-buffered saline (PBS) and resuspended in PBS at an ap-
propriate cell density. Mice were infected intranasally as previously de-
scribed (25). Briefly anesthetized mice were suspended by their incisors
on a thread. A yeast inoculumof 50l containing the appropriate number
of yeast cells was slowly dripped directly into the nares. Mice were left
suspended for an additional 10min andwere closelymonitored until they
recovered from anesthesia.Mice weremonitored daily and those showing
signs of morbidity (weight loss or extension of the cerebral portion of the
cranium) were sacrificed by CO2 asphyxiation.
Pulmonary fungal burden and cytokine analysis. At various time
points after infection, mouse organs were excised, weighed, and homog-
enized in 2 ml of PBS containing Complete protease inhibitor cocktail
tablet (Roche Diagnostics) using a Pro200 homogenizer (Pro Scientific,
Oxford, CT). Homogenates were serially diluted, plated on YPD agar, and
incubated at 30°C. Yeast colonies were counted after 2 to 3 days of incu-
bation. For pulmonary cytokine analysis, 0.05% Triton X-100 was added
to a portion of the homogenized lung lysate and the sample was incubated
for 2 h at 4°Cwith intermittentmixing. At the end of incubation, the lysate
was centrifuged at 12,000 g for 20 min. The supernatant was collected
and spun again for 20min at 12,000 g. Aliquots of the supernatant were
stored at80°C. Cytokine analysis was performed using the Bio-Plex pro
mouse cytokine 23-plex assay kit, following the protocol suppliedwith the
kit (Bio-Rad Laboratories, Hercules, CA). Fiftymicroliters of lung sample
was analyzed in each well.
Preparation of lung leukocyte single-cell suspensions. Mice were
sacrificed, and their left lungs were removed and added to homogeniza-
tion C tubes containing proprietary catalysts for mechanical and enzy-
matic digestion (Miltenyi Biotec, Auburn, CA). This was followed by ho-
mogenization of lung tissue in the gentleMACS dissociator based upon
the manufacturer’s instructions (Miltenyi Biotec). Homogenized tissue
was then passed through the 70-m-pore-size MACS SmartStrainer
(Miltenyi Biotec) and centrifuged at 300  g for 10 min to pellet cells.
Erythrocytes were removed using ACK (ammonium-chloride-
potassium) lysing buffer (Gibco, Grand Island, NY). Briefly, 1 ml of ACK
buffer was used to suspend pelleted cells. After a maximum of 10min, the
ACK lysing buffer was diluted 1:10 with complete RPMI medium. Cells
were then washed with cell staining buffer (CSB) containing final concen-
trations of 1 PBS (Corning Cellgro, Manassas, VA), 2 mMEDTA (Am-
resco, Solon, OH), and fraction V BSA (Fisher Scientific, Pittsburgh, PA).
Cells were then counted in a hemocytometer, using trypan blue staining to
exclude dead cells.
Fluorochrome-conjugated antibodies for flow cytometry. The fol-
lowing fluorochrome-conjugatedmouse antibodies fromBioLegend (San
Diego, CA) were used: peridinin chlorophyll protein (PerCP)-Cy5.5-
conjugated anti-CD45 antibody (Ab) (30-F11), phycoerythrin (PE)-
conjugated anti-CD24 Ab (30-F1), allophycocyanin (APC)-conjugated
anti-CD11c Ab (N418), PE-Cy7-conjugated anti-CD206 Ab (C068C2),
and PE-Cy7-conjugated anti-CD Ly-6GAb (1A8). The following BDBio-
sciences (San Jose, CA) fluorochrome-conjugated antibodies were also
used: BUV737-conjugated anti-CD11b Ab (M1/70), BV605-conjugated
anti-major histocompatibility complex class II (MHC-II) (M5/114.15.2),
BV421-conjugated anti-CD80Ab (16-10A1), Alexa Fluor 647-conjugated
anti-Siglec F Ab (E50-2440), BV711-conjugated anti-CD3e Ab (145-
2C11), Alexa Fluor 700-conjugated anti-CD4 Ab (RM4-5), BB515-
conjugated anti-CD25 Ab (PC61), APC-H7-conjugated anti-CD8a Ab
(53-6.7), BV605-conjugated anti-CD27 Ab (LG.3A10), PE-CF594-
conjugated anti-CD28 Ab (37.51), BV421-conjugated anti-CD183 Ab
(CXCR3-173), Alexa Fluor 647-conjugated anti-CD196 Ab (140706),
BUV737-conjugated anti-CD44 Ab (IM7), and PE-conjugated anti-
CD45RB Ab (16A).
Flow cytometry analysis of leukocyte populations. Briefly, cell sur-
face immunofluorescence staining involved the addition of 0.015 to
0.15 g of a fluorochrome-conjugated antibody mixture containing an-
tibodies specific to various leukocyte subpopulations to 25 l of an equal
mixture of CSB (defined above) and BD Horizon Brilliant stain buffer
(San Jose, CA) in the wells of a 96-well microtiter plate. This staining
mixture was then used to resuspend 2.5 105 cells in triplicate. Cells were
then incubated on ice for 30 min in the dark. This was followed by two
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washes with CSB, and then cells were fixed at 4°C overnight in 1% para-
formaldehyde (PFA). The next day, cells were washed and resuspended in
CSB and added to a 96-well microtiter plate for high-throughput flow
cytometry sampling using a BD LSRFortessa X-20 (BD Biosciences). BD
FACSDiva software was used to process samples on the flow cytometer,
and FlowJo (FlowJo, LLC, Ashland, OR) was used for data analysis of the
acquired samples to facilitate the identification of leukocyte populations.
Thirty thousand cell events were recorded, and dead cells and debris were
excluded based upon lower forward scatter (FSC) and side scatter (SSC)
signals (i.e., smaller size and granularity). Leukocyte populations were
identified by the following markers as previously described: eosinophils
(CD45 CD24 Siglec F), neutrophils (CD45 CD24 LY6G),
CD11b dendritic cells (DCs) (CD45 CD11b CD11c CD24MHC-
II), CD11b DCs (CD45 CD11b CD11c CD24MHC-II), alve-
olar (CD45 CD11b CD11c CD24 MHC-II) and interstitial
(CD45 CD11b CD11c CD24MHC-II) macrophages, Th1 CD4 T
cells (CD45 CD3 CD4 CD183 CD196), Th2 CD4 T cells (CD45
CD3 CD4 CD183 CD196), Th17 cells (CD45 CD3 CD4
CD183 CD196), regulatory T cells (Tregs) (CD45 CD3 CD4
CD25), CD8 cytotoxic T cells (CD45 CD3 CD8 CD28), and CD8
T suppressor cells (CD45 CD3 CD8 CD28) (34, 67, 68). The abso-
lute number of each leukocyte population was determined bymultiplying
the frequency of the leukocyte by the number of cells determined from the
single-cell suspensions and thenmultiplying by 2 to account for the whole
lung.
Statistical analysis. All statistical analyses were performed using
GraphPad Prism version 6.0 (GraphPad Software, Inc., San Diego, CA).
Statistical significance for survival studies was assessed by log-rank test.
Other group comparisons were performed by two-way analysis of vari-
ance (ANOVA) with Bonferroni’s multiple-comparison test.
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